Business Context and Reporting Period
This Form 8-K Current Report was filed by Illumina, Inc. on January 10, 2013, covering events occurring on January 6, 2013. The filing discloses the entry into a Material Definitive Agreement regarding the acquisition of Verinata Health, Inc.
Key Financial Metrics
The filing details the financial terms of the proposed merger but does not provide Illumina's standalone revenue, profit, cash flow, or debt metrics for the reporting period.
- Aggregate Consideration: $350 million (subject to closing and post-closing adjustments).
- Milestone Payments: Up to $100 million payable through 2015.
- Total Potential Value: Up to $450 million.
Material Changes
The primary material change is the execution of an Agreement and Plan of Merger. Under the agreement, TP Corporation (a wholly-owned subsidiary of Illumina) will merge with and into Verinata Health, Inc., with Verinata continuing as a wholly-owned subsidiary of Illumina. The transaction was approved by Verinata stockholders via written consent on January 6, 2013.
Outlook, Risks, and Contingencies
Consummation of the merger is subject to customary conditions, including the expiration or termination of applicable waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The agreement includes customary termination and indemnification provisions. The full text of the Merger Agreement is intended to be filed as an exhibit to Illumina's Annual Report on Form 10-K for the fiscal year ending December 30, 2012.
Investor Verification Checklist
- Verify the final closing date and whether the $350 million base consideration is adjusted.
- Confirm the specific performance metrics required to trigger the up to $100 million in milestone payments.
- Monitor the status of regulatory approvals under the Hart-Scott-Rodino Act.
- Review the full Merger Agreement text in the upcoming Form 10-K for detailed indemnification and termination clauses.